#8
VC3
Sheet 1 of 5
579-07

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OIPE JC139 FEB 07 2002 PATENT & TRADEMARK OFFICE

ATTY. DOCKET NO.	APPLICATION NO.
JAN-27	10/625,754 ~~10/008,516~~ ~~10/008,516~~
APPLICANT	CONFIRMATION NO.
Leventer et al.	Not yet assigned
FILING DATE	GROUP
11/8/01	~~Not yet assigned~~ 1614

RECEIVED
FEB 26 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CFO	1	3,736,315	05/29/73	Kórösi et al.	260	239	03/04/71
	2	4,322,346	03/30/82	Kórösi et al.	260	239	09/26/80
	3	4,423,044	12/27/83	Kórösi et al.	424	244	02/25/82
	4	4,614,740	09/30/86	Láng et al.	514	221	07/26/85
	5	4,835,152	05/30/89	Kórösi et al.	514	220	08/20/87
	6	5,204,343	04/20/93	Andrási et al.	514	221	10/17/91
	7	5,459,137	10/17/95	Andrási et al.	514	220	06/21/93
	8	5,521,174	05/28/96	Andrási et al.	514	220	06/07/95
	9	5,519,019	05/21/96	Andrási et al.	514	220	06/07/95
	10	5,639,751	06/17/97	Andrási et al.	514	220	06/07/95
	11	5,795,886	08/18/98	Anderson et al.	514	220	02/11/97
	12	5,891,871	04/06/99	Xia et al.	514	219	03/20/97
	13	6,017,965	01/25/00	Mueller et al.	514	649	12/11/96
	14	6,051,610	04/18/00	Mueller et al.	514	628	02/18/99
	15	6,071,970	06/06/00	Mueller et al.	514	648	06/07/95
	16	6,075,018	06/13/00	Vágó et al.	514	221	02/09/96
CFO	17	6,080,736	06/27/00	Landry et al.	514	221	10/27/99

EXAMINER R. A. Hutzell

8/4/04
DATE CONSIDERED
1/2/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. JAN-27	APPLICATION NO. 10/625,754 ~~10/008,516~~
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Leventer et al.	CONFIRMATION NO. Not yet assigned
	FILING DATE 11/8/01	GROUP ~~Not yet assigned~~ 1614

OIPE JC139 FEB 07 2002 PATENT & TRADEMARK OFFICE

TECH CENTER 1600/2900 FEB 26 2002 RECEIVED

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
CTO 18	CA 2,057,504	06/22/92	Canada	—	—		
19	DT 2122 070	06/08/72	Germany	—	—	X	
20	EP 0 492 485	07/01/92	EPO	—	—		
21	HU 178516	09/28/81	Hungary	—	—	X	
22	WO 91/17159	11/14/91	PCT	—	—		
23	WO 92/11262	07/09/92	PCT	—	—		
CTO 24	WO 95/01357	01/12/95	PCT	—	—		

EXAMINER [signature] [signature]

DATE CONSIDERED 8/4/04 1/2/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. JAN-27	APPLICATION NO. 10/625,754 ~~40/008,516~~
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Leventer et al.	CONFIRMATION NO. Not yet assigned
	FILING DATE 11/8/01	GROUP ~~Not yet assigned~~ 1614

OIPE JC139 FEB 07 2002 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
OTO 25	S. Almquist et al., "Direct and Indirect Approaches to Enantiomeric Separation of Benzodiazepines Using Micro Column Techniques," J. Chromatography A, 679:139-146 (1994).
26	N. Bargmann-Leyder et al., "A Comparison of LC and SFC for Cellulose- and Amylose-Derived Chiral Stationary Phases," Chirality, 7:311-325 (1995).
27	A. Bond and M. Lader, "A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam," Eur. J. Clin. Pharmacol., 22:137-142 (1982).
28	M. Briley et al., "Tofisopam Enhances the Anticonvulsant Activity of Diazepam Against Some, but Not All, Convulsive Agents," British J. Pharm., 82:300P (1984).
29	G. De Sarro et al., "GYKI 52466 and Related 2,3-benzodiazepines as Anticonvulsant Agents in DBA/2 Mice," Eur. J. Pharmacol., 294:411-422 (1995).
30	I. Fellegvári et al., "Separation of Conformational Diastereomers of 2,3-Benzodiazepines by HPLC," *Chromatography* in *Symposia Biologica Hungarica*, H. Kalász and L.S. Ettre, Eds., 193-203 (1987).
31	V. Filip et al., "A Double-Blind, Placebo-Controlled Study with Tofizopam in Anxiety Neurosis," Agressologie, 22:27-30 (1981).
32	I. Fitos et al., "Separation of Enantiomers of Benzodiazepines on the Chiral-AGP Column," J. Chromatography A, 709:265-273 (1995).
33	E. Fogassy et al., "Studies on the Properties and Structure of Optically Active 1-(3,4-Dimethoxyphenyl)-4-Methyl-5-Ethyl-7,8-Dimethoxy-5H-2,3-Benzodiazepine (Tofizopam)," in *Bio-Organic Heterocycles*, H.C. van der Plas, L. Ötvös, and M. Simonyi, Eds., 229-233 (1984).
34	H. Goldberg et al., "Comparative Efficacy of Tofisopam and Placebo," Am. J. Psychiatry, 136:196-199 (1979).
35	K. Imre et al., "A Tofizopam (Grandaxin®) Farmakokinetikaja es Metabolizmusa," Acta Pharmaceutica Hungarica, 63:83-90 (1993).
36	C. Ito, "Behavioral Pharmacological Study on the Structure Activity Relationship of Benzodiazepine Derivatives: with Particular Reference to the Activity of 2,3-Benzodiazapine," J. Tokyo Med. College, 39:369-384 (1981).
37	J. Kanto et al., "Tofizopam: a Benzodiazepine Derivative without Sedative Effect," Intl. J. Clin. Pharm. Ther. Tox., 20:309-312 (1982).
38	K. Maier et al., "The Effect of Tofisopam on Psychic Performance in Persons With More Than Average Anxiety: A Controlled Experimental Trial," Current Therapeutic Research, 35(4):541-548 (1984).
OTO	"Tofisopam", Martindale, Royal Pharmaceutical Society of Great Britain, p. 620, col. 1 (1993).

EXAMINER [signature] DATE CONSIDERED 8/4/04 11/2/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. JAN-27	APPLICATION NO. 10/625,754 ~~10/008,516~~
	APPLICANT Leventer et al.	CONFIRMATION NO. Not yet assigned
	FILING DATE 11/8/01	GROUP ~~Not yet assigned~~ 1614

OIPE JC139 FEB 07 2002 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL		
CTO	39	T. Mennini et al., "Brain Levels of Tofisopam in the Rat and Relationship with Benzodiazepine Receptors," Arch. Pharmacol., 321:112-115 (1982).
	40	J. Molcan et al., "Tofizopam in the Therapy of Anxious-Depressive Syndroms," Agressologie, 22:23-24 (1981).
	41	F. Pal, "A Grandaxin® Gyógyszertechnológiája," Acta Pharmaceutica Hungarica, 63:67-78 (1993).
	42	Pakkanen et al., "Comparative Study of the Clinical Effects of Tofizopam, Nitrazepam and Placebo as Oral Premedication," British J. Anaesthesia, 1009-1012 (1980).
	43	S. Pellow and S. File, "The Effects of Tofisopam, a 3,4-Benzodiazepine, in Animal Models of Anxiety, Sedation, and Convulsions," Drug Dev. Res., 7:61-73 (1986).
	44	L. Petócz and I. Kosóczky, "The Main Pharmacological Characteristics of Grandaxin (Tofisopam, EGYT-341)," Ther. Hungarica, 23:134-138 (1975).
	45	L. Petócz, "The Pharmacological Effects of Tofisopam (Grandaxin)®," Acta Pharmaceutica Hungarica, 63:79-82 (1993).
	46	V. Saano and A. Urtti, "Tofizopam Modulates the Affinity of Benzodiazepine Receptors in the Rat Brain," Pharm. Biochem. Behavior, 17:367-369 (1982).
	47	V. Saano, "Tofisopam Selectively Increases the Action of Anticonvulsants," Med. Biol., 64:201-206 (1986).
	48	V. Saano et al., "Tofisopam Enhances the Action of Diazepam Against Tremor and Convulsions,' Med. Biol., 61:49-53 (1983).
	49	T. Seppälä et al., "Tofisopam, a Novel 3,4-Benzodiazepine: Multiple-Dose Effects on Psychomotor Skills and Memory. Comparison with Diazepam and Interactions with Ethanol," Psychopharmacology, 69:209-218 (1980).
	50	M. Simonyi and I. Fitos, "Stereoselective Binding of a 2,3-Benzodiazepine to Human Serum Albumin," Biochemical Pharmacology, 32(12):1917-1920 (1993).
	51	R. Sladkà et al., "A Placebo-controlled Clinical Trial With Tofizopam in the Treatment of Anxiety Neurosis," Ther. Hungarica, 27:176-180 (1979).
CTO	52	J. Szegó et al., "Selected Passages From the Clinical-Pharmacological and Clinical Trials of Grandaxin®," Acta Pharmaceutica Hungarica, 63:91-98 (1993).

EXAMINER RDH/HJR DATE CONSIDERED 8/4/04 1/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. JAN-27	APPLICATION NO. 10/625,754 ~~10/008,516~~
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Leventer et al.	CONFIRMATION NO. Not yet assigned
	FILING DATE 11/8/01	GROUP Not yet assigned

OIPE JC139 FEB 07 2002 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
CTO 53	G. Toth et al., "Racemate Splitting of (±)-5-ethyl-1-(3,4-dimethoxyphenyl)-6,7-dimethoxy-4- methyl-5H-2,3-benzodiazepine an Anomalous Chiroptic Behavior of Enantiomer (1)," J. Heterocyclic Chem., 20:709-713 (1983).
54	G. Várady et al., "The Clinical Evaluation of Grandaxin Used in the Treatment of Outpatients (A Multicentric Study)," Ther. Hungarica, 23:153-158 (1975).
55	J. Visy and M. Simonyi, "The Role of Configuration and Conformation in the Binding of 2,3-Benzodiazepines to Human Serum Albumin," Chirality, 1:271-275 (1989).
CTO 56	F. Zsila et al., "Separation and Identification of Tofisopam and Steroisomers by Hyphenated HPLC-CD Technique," J. Liq. Chrom. & Rel. Technol., 22:713-719 (1999).

EXAMINER [signature] DATE CONSIDERED 8/4/04 1/2/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.